Position in VRTX
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$251,842
+$44,201 QoQ
Shares Held
507
+9.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#1,287
of 1,705 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in VRTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Banque Transatlantique SA holds $4,701,531 across 15 Biotechnology names. VRTX ranks #5 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
6,752 | $1,652,687 | |
| 2 | MRNA |
Moderna, Inc.
|
21,793 | $1,526,163 | |
| 3 | IMCR |
Immunocore Holdings plc
|
10,150 | $322,262 | |
| 4 | ARGX |
Argenx SE
|
327 | $303,380 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
507 | $251,842 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
692 | $208,312 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
254 | $158,379 | |
| 8 | INCY |
Incyte Corp
|
970 | $109,959 |
All Filings in VRTX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $251,842 | 507 | Shares | Defined | 2026-07-30 | |
| 2026-03-31 | $207,641 | 465 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $244,361 | 539 | Shares | Defined | 2026-02-26 | |
| 2025-09-30 | $240,466 | 614 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $345,475 | 776 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $399,491 | 824 | Shares | Defined | 2025-09-09 | |
| 2024-12-31 | $246,452 | 612 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||